When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. PARP inhibitor - Wikipedia

   en.wikipedia.org/wiki/PARP_inhibitor

   Side effects of PARP inhibitor treatment for cancer may include neutropenia, and a risk of anaemia. [25] People who take this medication also commonly report fatigue. [ 25 ] The toxicity profile of PARP inhibitors when treating cancer has not been found to be more serious than chemotherapy agents, however, further research is needed to ...

3. Niraparib - Wikipedia

   en.wikipedia.org/wiki/Niraparib

   [3] [4] It is a PARP inhibitor. The most common side effects include nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anemia (low red blood cell counts), constipation, vomiting, abdominal (belly) pain, neutropenia (low levels of neutrophils, a type of white blood cell), insomnia (difficulty sleeping ...

4. Selinexor - Wikipedia

   en.wikipedia.org/wiki/Selinexor

   Selinexor sold under the brand name Xpovio among others, is a selective inhibitor of nuclear export used as an anti-cancer medication.It works by blocking the action of exportin 1 [6] and thus blocking the transport of several proteins involved in cancer-cell growth from the cell nucleus to the cytoplasm, which ultimately arrests the cell cycle and leads to apoptosis. [8]

5. Management of prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Management_of_prostate_cancer

   Side effects of radiation therapy might occur after a few weeks into treatment. Both types of radiation therapy may cause diarrhea and mild rectal bleeding due to radiation proctitis, as well as potential urinary incontinence and impotence. Symptoms tend to improve over time except for erections which typically worsen as time progresses.

6. Veliparib - Wikipedia

   en.wikipedia.org/wiki/Veliparib

   Veliparib (ABT-888) [1] is a potential anti-cancer drug acting as a PARP inhibitor.It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments.

7. Olaparib - Wikipedia

   en.wikipedia.org/wiki/Olaparib

   In January 2018, olaparib was approved in the United States for the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any ...